CHICAGO--(BUSINESS WIRE)--Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina Ventures. Other investors include DCVCBio, Civilization Ventures, EGB Capital, and Portal Innovations.

芝加哥--（商业新闻短讯）--Syntax Bio是一家临床前阶段的生物技术公司，在Astellas Venture Management LLC和Illumina Ventures的支持下成立。其他投资者包括DCVCBio、文明风险投资、EGB资本和门户创新。

The Syntax Cellgorithm platform mimics human developmental processes at the epigenetic level, using a modified CRISPR system to regulate endogenous genes in an automatic and temporally controlled manner. To date, Syntax Bio has raised $15 million to advance its cell differentiation discovery platform and was co-founded by Ryan Clarke, PhD, and Professor Brad Merrill, PhD, from the University of Illinois at Chicago..

Syntax Cellgorithm平台在表观遗传水平上模拟人类发育过程，使用改进的CRISPR系统以自动和时间控制的方式调节内源基因。迄今为止，Syntax Bio已经筹集了1500万美元来推进其细胞分化发现平台，由芝加哥伊利诺伊大学的Ryan Clarke博士和Brad Merrill教授共同创立。。

'We believe that making cell therapy more accessible hinges on reducing costs by streamlining the manufacturing process, and Syntax Bio’s innovative approach offers a potentially promising solution to current industry challenges,' noted William Watt, PhD, President of Astellas Venture Management LLC..

Astellas Venture Management LLC总裁威廉·瓦特（William Watt）博士指出：“我们认为，使细胞疗法更容易获得取决于通过简化制造过程来降低成本，而Syntax Bio的创新方法为当前的行业挑战提供了潜在的有希望的解决方案。”。。

“Cellgorithm technology mimics natural developmental processes by directly activating programs in the human genome and providing instruction sets to make specific cell types,” said Andy May, DPhil, Executive Chairperson of Syntax Bio and Entrepreneur-in-Residence, DCVCBio.

“Cellgorithm技术通过直接激活人类基因组中的程序并提供指令集来制造特定的细胞类型，从而模仿自然发育过程，”Syntax Bio执行主席兼DCVCBio常驻企业家安迪·梅（AndyMay）说。

By accelerating cell differentiation, Syntax Bio’s technology significantly reduces the time required to generate high-value cell types, overcoming longstanding challenges in stem-cell-derived therapies.

通过加速细胞分化，Syntax Bio的技术大大减少了产生高价值细胞类型所需的时间，克服了干细胞衍生疗法的长期挑战。

Ron Mazumder, PhD, Partner at Illumina Ventures said, 'Syntax’s technology is a powerful system with the potential to democratize the cell therapy industry. We are eager to support Syntax in this endeavor.'

Illumina Ventures合伙人RonMazumder博士说，“Syntax的技术是一个强大的系统，有可能使细胞治疗行业民主化。我们渴望在这项工作中支持语法。”

About Syntax

关于语法

Syntax Bio is a preclinical-stage biotechnology company based in Chicago that is focused on generating therapeutic-grade cells from stem cells leveraging its novel Cellgorithm platform technology.

Syntax Bio是一家位于芝加哥的临床前阶段生物技术公司，专注于利用其新型Cellgorithm平台技术从干细胞中产生治疗级细胞。

To learn more about Syntax Bio, please visit https://www.syntax-bio.com/

要了解有关Syntax Bio的更多信息，请访问https://www.syntax-bio.com/